Cosmos Health Inc. Stock Price, News & Analysis

Cosmos Health Inc. (Nasdaq:COSM) announced that its UK subsidiary, Decahedron Ltd., has been recognized as "Pharmaceutical Wholesaler of the Month" in the Mar/Apr 2023 issue of Healthcare Matters. Established in 2011, Decahedron Ltd. specializes in the import and export of pharmaceutical products across the EEA. The feature highlights Cosmos Health's Sky Premium Life brand, which offers over 75 nutraceutical products tailored for diverse dietary needs. CEO Greg Siokas noted the honor reflects the company's commitment to operational excellence and marketing innovations. Decahedron has expanded its product promotions globally, participating in key health exhibitions.

Cosmos Health (Nasdaq:COSM) announced on March 17, 2023, that it has signed a definitive agreement to acquire ZipDoctor Inc. from American International Holdings Corp. The acquisition aims to enhance Cosmos Health's presence in the rapidly growing telehealth market, projected to expand from $23.8 billion in 2021 to $309.9 billion by 2030, with a CAGR of 45.1%. ZipDoctor provides a subscription-based telemedicine service offering 24/7 access to healthcare professionals. The transaction is set to close on April 3, 2023, and is expected to support Cosmos Health's goal to broaden ZipDoctor's healthcare services, including mental health and wellness treatments.

Cosmos Health (Nasdaq:COSM) announced a definitive agreement with Pharmaceutical Laboratories CANA S.A., a Greek pharmaceutical company, following a Binding Letter of Intent dated July 19, 2022. Cosmos injected €4.1 million into Cana on February 28, 2023, strengthening its balance sheet to facilitate future growth. This transaction aims to enhance vertical integration, expand the product portfolio, and accelerate growth plans, including entering new business segments. Cana, established in 1928, offers a diverse range of pharmaceutical products and operates an EU-licensed production facility. The Stock Purchase Agreement is expected to conclude by March 31, 2023.

Cosmos Health Inc. (Nasdaq: COSM) has entered the final stages of acquiring ZipDoctor Inc., a telemedicine platform, from American International Holdings Corp.. This acquisition aims to enhance Cosmos Health's portfolio by providing 24/7 access to healthcare professionals through a subscription model. ZipDoctor will serve U.S. customers with both English and Spanish virtual visits. The U.S. telehealth market is projected to grow significantly, from $23.8 billion in 2021 to $309.9 billion by 2030, with a CAGR of 45.1%. The acquisition aligns with Cosmos' strategy to expand its healthcare services, particularly in telehealth.

Cosmos Health (Nasdaq:COSM) has extended its non-binding letter of intent (LOI) to acquire ZipDoctor Inc., a telemedicine platform, from American International Holdings Corp until February 24, 2023. ZipDoctor provides direct-to-consumer telemedicine services, offering 24/7 access to certified physicians and mental health professionals across the U.S.

The telehealth market is projected to grow from $23.8 billion in 2021 to $309.9 billion by 2030, driven by a shortage of healthcare professionals. Cosmos plans to expand ZipDoctor's service offerings, enhancing its competitive position in this rapidly growing sector.

Cosmos Health Inc. (NASDAQ: COSM) has announced its first purchase order for the distribution of Virax Biolabs' COVID-19 and Influenza A+B Antigen Combo Rapid Detection Kits. The agreement grants Cosmos exclusive distribution rights for Greece and Cyprus and the opportunity to expand distribution across Europe. The single-use test kit offers a qualitative detection method for COVID-19 and Influenza A+B from nasal swab specimens. CEO Greg Siokas expressed optimism about meeting the strong demand for quick testing solutions in these regions and emphasized the company's solid financial position to build strategic partnerships.

Virax Biolabs Group Limited (Nasdaq: VRAX) has announced a Purchase Order with Cosmos Health (Nasdaq: COSM) to launch COVID-19 and Influenza A+B Antigen Combo Rapid Detection Kits. This follows their distribution agreement from September 2022, granting Cosmos exclusive rights in Greece and Cyprus, with potential for broader distribution across Europe. The rapid tests, designed for qualitative detection of viral antigens, provide results in just 15 minutes. The partnership aims to address significant health challenges posed by COVID-19 and influenza, which collectively account for millions of severe illnesses and deaths globally.

Cosmos Health Inc. (Nasdaq:COSM) has initiated the application process for a dual listing on Upstream, a platform for digital securities and NFTs, to attract a global investor base. This move aims to enhance liquidity and price discovery by allowing trades in USDC digital currency, credit, debit, PayPal, and USD. CEO Greg Siokas emphasized the importance of accessing a wider audience to increase shareholder value. The approval for listing is subject to MERJ's acceptance, but Cosmos Health may qualify for an expedited process due to its NASDAQ status.

Cosmos Health Inc. (Nasdaq:COSM) announced the appointment of Nikos Bardakis as Chief Operating Officer, bringing over 20 years of international experience in the pharmaceutical sector. Bardakis aims to enhance operational excellence and drive global expansion of Cosmos' premium products. He previously served as National Sales Director at Servier Hellas, managing over 130 employees. Bardakis succeeds Pavlos Ignatiades, who transitions to Chief Communications Officer, focusing on consistent messaging and stakeholder communication. CEO Greg Siokas expressed confidence in the leadership changes, aligning with the company's growth strategy and transition to focus on health and wellness.